Sunday, November 2, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

RBC Capital Analyst Reaffirms Outperform Rating for Zillow Gr with 66 Price Target

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
Finances
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

On March 7, 2024, Brad Erickson, an analyst at RBC Capital, has once again endorsed Zillow Gr (NASDAQ: ZG) with an Outperform rating and a $66 price target. This vote of confidence suggests that RBC Capital is optimistic about Zillow Gr’s prospects in the market.

Zillow Group, Inc. (ZG) Stock Shows Stability and Strength on March 7, 2024

Zillow Group, Inc. (ZG) had a relatively stable performance on March 7, 2024, as the stock closed at $54.06, a slight increase of $0.03 from the previous market close. This represents a 0.06% rise in the stock price for the day. ZG is currently trading near the top of its 52-week range and above its 200-day simple moving average, indicating that the stock has been performing well. Despite remaining unchanged in after-hours trading, investors may be waiting to see how the stock performs in the coming days. Overall, ZG’s performance on March 7th was relatively stable, showing signs of strength by trading near its 52-week high and above its 200-day moving average. Investors will be watching closely to see if the positive momentum continues.

ZG Stock Performance Review: Flat Revenue but Decrease in Net Income and EPS Raises Concerns

On March 7, 2024, ZG stock’s performance was under scrutiny as the company released its financial data for the past year and the fourth quarter. According to CNN Money, ZG reported a total revenue of $1.95 billion for the past year, which remained flat compared to the previous year. The total revenue also remained flat at $474.00 million for the fourth quarter.

However, the net income for ZG told a different story. The company reported a net income of -$158.00 million for the past year, which was a decrease of 56.44% compared to the previous year. The net income for the fourth quarter was even worse, at -$73.00 million, indicating a significant decrease of 160.71% compared to the previous quarter.

Similarly, the earnings per share (EPS) for ZG also took a hit. The EPS was reported at -$0.68 for the past year, a decrease of 62.17% compared to the previous year. The EPS for the fourth quarter was even worse, at -$0.31, indicating a decrease of 161.08% compared to the previous quarter.

Overall, the financial performance of ZG on March 7, 2024, was not very positive. While the total revenue remained flat, the net income and EPS showed significant decreases, indicating potential challenges for the company in the coming quarters. Investors and analysts will be closely monitoring ZG’s performance in the future to see if the company can turn things around and improve its financial health.

Tags: ZG
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Markets and money

Analyst Ratings and Price Targets for Legend Biotech

Retail Stock Bull Market

Analyst Revises Price Target for Foot Locker Based on Market Conditions

Food Producers Stock Exchange

Analysts Bullish on BellRing Brands Strong Buy Recommendations and Positive Outlook

Recommended

Biotechnology Stock Bull Market

Groundbreaking Licensing Agreement to Develop RNAi Therapy for FSHD

2 years ago
Silber Stock

Silver Soars to 14-Year Peak as Industrial Demand Intensifies

4 weeks ago
CRWD stock news

Open Text Surpasses Expectations with Strong Q2 Earnings and Revenue Growth

2 years ago
Biotechnology Trading online

Leonardo DRS Exceeds Expectations with Impressive FourthQuarter 2023 Results

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

D-Wave Quantum’s Technical Breakthrough Offsets Mixed Quarterly Results

Analyst Consensus: Kanzhun Stock Receives Overwhelming Buy Endorsement

Biogen’s Market Paradox: Strong Quarterly Performance Clashes with Cautious Outlook

Ameren’s Q3 2025 Earnings Report: A Critical Test for the Utility Giant

Anixa Biosciences Emerges as Promising Contender in Cancer Treatment Race

The Trade Desk: Analysts Project Significant Upside Ahead of Earnings

Trending

VanEck Merk Gold Trust Stock
Commodities

Gold’s Consolidation Phase: A Pause in the Meteoric Rise?

by Andreas Sommer
November 2, 2025
0

The dazzling rally in gold appears to be taking a breather. Having soared past the historic $4,000...

Blue Owl Capital Stock

Market Contradiction: Blue Owl Capital’s Strong Performance Meets Investor Skepticism

November 2, 2025
Embraer Stock

Embraer Faces Critical Earnings Test as Key Metrics Come Into Focus

November 2, 2025
D-Wave Quantum Stock

D-Wave Quantum’s Technical Breakthrough Offsets Mixed Quarterly Results

November 2, 2025
KanzhunADR Stock

Analyst Consensus: Kanzhun Stock Receives Overwhelming Buy Endorsement

November 2, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Gold’s Consolidation Phase: A Pause in the Meteoric Rise?
  • Market Contradiction: Blue Owl Capital’s Strong Performance Meets Investor Skepticism
  • Embraer Faces Critical Earnings Test as Key Metrics Come Into Focus

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com